Zymogenetics, Inc.

Eugene C Yi

Stephen R Jaspers

Stacey R Dillon

Mark W Rixon

Cecile Krejsa

Frederick J Ramsdell

Pallavur V Sivakumar

Zeren Gao

Brian A Fox

Wenfeng Xu

Cameron Brandt

Jacob J Kennedy

Scott R Presnell

Debra G Gilbertson

Yue Yao

George Robert Mabry, Iii

Marshall D Snavely

Cameron S Brandt

Cecile M Krejsa

George R Mabry

Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

B7 family member zB7H6 and related compositions and methods

Disclosed are antagonists of PDGF receptor &#x3b2; (PDGFR&#x3b2;) and VEGF-A, including neutralizing anti-PDGFR&#x3b2; and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR&#x3b2; and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR&#x3b2; and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR&#x3b2; and/or VEGF-A antagonist.

Compositions and methods for inhibiting PDGFRbeta and VEGF-A

Compositions and methods for inhibiting PDGFR&#x3b2; and VEGF-A

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21  antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, Tcells or T17 cells.

Methods of treatment using anti-human IL-21 monoclonal antibodies

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Anti-human IL-21 monoclonal antibodies

Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells Tcells or T17 cells.

Anti-zB7H6 antibody-drug conjugates

Growing community of inventors

Mill Creek, WA, United States of America

Eugene C Yi